Clovis Oncology Investor Relations Material
Latest events
Q2 2022
Clovis Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Clovis Oncology Inc
Access all reports
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company's clinical trial programs comprise three drug candidates designed to inhibit the growth of cancer tumors. Its lead product candidate is NDA 20-538 for metastatic adenocarcinoma of the pancreas; and other preclinical assets include NK-1 receptor antagonists for the treatment of inflammatory bowel disease; glio-selectins for the treatment of glioblastoma multiforme; and JTK inhibitors for multiple indications. Clovis Oncology markets its products through a limited direct sales force in the majority of its markets. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
CLVS
Country
🇺🇸 United States